Abstract
Background
The microRNAs let-7 g and miR-221 have been demonstrated to be related to the glucose metabolism. This study assessed the serum levels of these two microRNAs in subjects with and without metabolic syndrome (MetS).
Results
The serum microRNA levels were detected in 102 subjects aged 40 to 80 years who were recruited from the general population. The status of MetS was defined by the Adult Treatment Panel III (ATP III) criteria modified for Asians. Subjects with histories of cardiovascular diseases or who were receiving treatment with hypoglycemic or lipid-lowering agents were excluded. The levels of both circulating microRNAs (let-7 g and miR-221) were higher in subjects with MetS (p = 0.004 and p = 0.01, respectively). The sex-specific analysis showed that the difference was more prominent in women (for both miRNAs, p < 0.05 in women and p > 0.1 in men). In the female subjects, increased expression of both microRNAs was associated with an increased number of MetS risk components (p = 0.002 for let-7 g and p = 0.022 for miR-221). Moreover, the elevation of serum let-7 g was significantly associated with a low level of high-density lipoprotein cholesterol (p = 0.022) and high blood pressure (p = 0.023). In contrast, the miR-221 level was not associated with any individual MetS risk component.
Conclusions
The circulating levels of let-7 g and miR-221 displayed a female-specific elevation in individuals with metabolic syndrome.
Keywords: Obesity, Gender disparity, let-7 g, miR-221
Background
Metabolic syndrome (MetS) has become a global health issue due to its contribution to an increased risk of type 2 diabetes, cardiovascular (CV) complications, and mortality. MetS features a clinical phenotype of abdominal adiposity, insulin resistance, hypertension, dyslipidemia, inflammation, and a prothrombotic state. The associations between MetS and chronic inflammation [1], insulin resistance [2], or incident CV events [3] have been presented differently between men and women. Furthermore, a recent study demonstrated that gender is a significant effect modifier for MetS-related CV deaths, non-CV deaths, and total mortality [4].
MicroRNAs (miRNAs), which are endogenous non-coding small RNAs, are involved in the post-transcriptional regulation of gene expression through the suppression of mRNA translation or the degradation of mRNA. More than 60% of the human protein-coding genes are expected to have miRNA target sites in their 3’-untranslated region (3’-UTR); therefore, miRNAs are considered to likely be involved in the pathogenesis of diseases [5-8]. An ample of evidence indicates that miRNAs can be detected in the circulation [9,10]. After being released into the extracellular fluids, miRNAs play roles in cell-to-cell communication within the same tissue or between the same and different cell types in remote tissues by the methods of endocytosis-like internalization or receptor-ligand interactions [11].
One recent study compared subjects with MetS to individuals manifesting only one of metabolic disorders [type 2 diabetes, hypercholesterolemia, or hypertension] showed that blood miR-197, miR-23, and miR-509-5p positively correlated with body mass index, and elevated circulating miR-130a and miR-195 were associated with high blood pressure [12]. Using in silico analysis, the authors predicted that the target genes of these 5 miRNAs may involve in the pathways related to shingolipid and fatty acid metabolisms and the vascular signaling. Metabolic syndrome is a diseased condition which affects both adipose tissue and vascular walls. Extracellular miRNAs may mediate the intercellular communication. The adipocyte-derived microvesicles contained not only bioactive proteins but also miRNAs, including let-7b and miR-103, 143, 146b, 148, 155, and 221 [13]. Of these, let-7b, miR-143, and 221 have been demonstrated to regulate both atherogenic and adipogenic processes [13]. Heneghan et al. compared the expression profiles of circulating miRNAs between morbidly obese patients and non-obese individuals and found miR-132 and miR-17-5p were significantly decreased in obese subjects [14]. The level of miR-17-5p inversely correlated with body mass index and it may regulate adipocyte differentiation by targeting Rb2/p130. In the same article, the data did not confirm differences in the levels of circulating miR-34a, 99a, 122, 143, 145, and 195 between subjects in the two groups. However, the authors did not make a mention of let-7 or miR-221.
Previous publications have indicated that the let-7 family plays an important role in glucose metabolism. Using Cre-inducible let-7-transgenic mice, Frost and Olson [15] reported that the global overexpression of let-7 resulted in glucose intolerance and decreased insulin secretion from the pancreas. The knockdown of let-7 can prevent and treat obesity-induced glucose intolerance by restoring the expression of the insulin receptor and insulin receptor substrate 2 in the muscle and liver of mice fed a high-fat diet [15]. Zhu et al. also found that Lin28a/b and let-7 can coordinately regulate the glucose metabolism through the activation and suppression of the insulin-PI3K-mTOR signaling pathway, respectively [16]. In vitro studies have shown that high glucose (HG) upregulates miR-221 expression in human umbilical vein endothelial cells and results in impaired endothelial cell migration through the suppression of the c-kit gene [17]. A reduction of the miR-221 levels through its anti-sense oligonucleotide could restore the production of the c-kit protein and weaken the HG-induced inhibition of cell migration. The levels of miR-221 are increased in adipocytes derived both from mice under a high-fat diet [18] and obese human subjects [19]. In addition, miR-221 can be upregulated in 3 T3-L1 adipocytes treated with tumor necrosis factor-alpha [20].
In the present study, we have found the association of two circulating microRNAs (let-7 g and miR-221) with metabolic syndrome in human subjects, more prominent in women. The over-expression of the two microRNAs in the circulation may have implications for MetS related CV complications.
Methods
Study population and definition of metabolic syndrome
The subjects in this study (aged between 40 and 80 years) were enrolled from the general population who had volunteered to participate in ongoing genetic studies related to cardiovascular diseases and metabolic syndrome at the Kaohsiung Medical University Hospital between Jan 2010 and Sep 2011. All of the participants provided written informed consent. To reduce the effect from existing major cardiovascular diseases, subjects who self-reported coronary artery disease, myocardial infarction, stroke, or peripheral arterial occlusive disease were excluded from the study. In addition, subjects who were taking medication for hyperglycemia or hyperlipidemia were also excluded. At the study entry, 122 subjects were enrolled but 20 were excluded due to the presence of hemolysis. Metabolic syndrome was diagnosed in patients who exhibited three or more of the following symptoms, which are defined by the Adult Treatment Panel (ATP) III criteria modified for Asians: 1) waist circumstance greater than 90 cm in men and greater than 80 cm in women, 2) systolic blood pressure greater than 130 mmHg, diastolic blood pressure greater than 85 mmHg, or previously diagnosed hypertension with treatment, 3) fasting glucose level greater than 100 mg/dl or previously diagnosed diabetes mellitus with treatment, 4) fasting triglycerides greater than 150 mg/dl, and 5) high-density lipoprotein (HDL) cholesterol less than 40 mg/dl in men and less than 50 mg/dl in women. The classification of metabolic syndrome from 0–5 was based on the number of abnormal metabolic components defined by the above criteria. A subject who reported never having smoked was defined as a never smoker. A subject who had previously smoked in his/her lifetime was defined as a smoker. Because the median age of natural menopause in Chinese women is 50 years [21,22], we further separated the women by this age cutoff for an exploratory analysis.
Serum preparation and hemoglobin measurement for hemolysis
Within 1 h after sample collection, the fasting venous blood was centrifuged at 3,000 g and 4°C for 10 min. The serum was stored immediately at -80°C until further use. To determine the degree of hemolysis in the samples, 200 μl of sodium carbonate solution (0.01% Na2CO3) was added to 20 μl of each serum sample (10:1 dilution). After vortex mixing and incubating at room temperature for 1 h, the free oxy-hemoglobin in the serum was measured using a spectrophotometer at an absorbance wavelength of 415 nm (A415) [23]. Higher levels of the absorbance peak indicated a higher degree of hemolysis in the serum. The cutoff A415 value of 0.2 was used to distinguish the hemolyzed from the non-hemolyzed samples [24].
Isolation of total RNA and miRNA from serum
The serum total RNA, including miRNAs, was extracted using the MasterPure™ Complete DNA and RNA Purification Kit (Epicentre, an Illumina company, USA) according to the manufacturer’s instructions. After effective denaturation of the proteins in serum during RNA isolation, we added 1 μl of 5 nM synthetic, non-human miRNA (syn-cel-lin-4) into 50 μl of each serum sample as an internal control for the normalization of the real-time PCR results. The final RNA products were quantified by absorbance measurements at 260 nm (A260) and 280 nm (A280). The A260/A280 values were higher than 1.6 for all of the samples.
Quantification of miRNAs: real-time quantitative PCR
The mature miRNAs were measured using TaqMan-based qRT-PCR methods according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). The reverse transcription reactions were performed in scaled-down reaction volumes (8 μl) under the following conditions: 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. The real-time PCR reactions were performed in duplicate in scaled-down reaction volumes (10 μl) on an ABI Prism 7900 Sequence Detection System under the following conditions: 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. The data were analyzed using the SDS Software version 2.4 (Applied Biosystems, Inc.), and a miRNA with a Ct value greater than 36 was considered undetectable. The analysis across the samples was conducted using a median normalization method with a spiked-in synthetic C. elegans miRNA (syn-cel-lin-4) as the control [10]. The normalization factors were obtained after subtracting the measured Ct of syn-cel-lin-4 for each sample of interest from the median value of all of the samples. Then, the normalization factor was added to the raw Ct of every candidate miRNA in the same sample. Finally, the adjusted data (Ct’) was treated as the median-normalized Ct value. The expression level of a circulating miRNA was calculated as 2-Ct’ with a logarithmic transformation.
Statistical analysis
JMP (version 8.0) and PASW Statistics (version 18) were used for all statistical analyses. To evaluate the baseline characteristics and the risk components of MetS, Chi-square analyses and t-test were applied for the categorical and continuous variables, respectively. Comparisons of the levels of circulating miRNAs between the two groups were conducted by the non-parametric Mann–Whitney U tests because the data were not normally distributed. The relationship between the number of MetS components and the expression of both miRNAs was tested through the Jonckheere-Terpstra test. Correlation coefficients were used to examine the relationships between the value of each MetS risk component and the expression level of a miRNA. A difference with p < 0.05 was considered statistically significant.
Results
Clinical characteristics of the study population
Because hemolysis can increase the serum microRNA levels due to red blood cells (RBC)-derived microRNAs [24], we excluded 20 serum samples that exceeded the hemolysis cutoff value (see Method section for details). Therefore, 102 samples were subjected to further analysis. The demographic characteristics and the status of MetS in these 102 subjects are shown in Table 1. There were 31 MetS subjects and 71 non-MetS. In general, the distributions of sex, age, prevalence of diabetes, and smoking status were similar between the groups with or without MetS. The characteristics between men and women in respect of their MetS status are also shown in Table 1. The prevalence of each risk component between genders according to the sum of abnormal components of the MetS is shown in Table 2. Of the five components of MetS, large waist circumstance was the most common risk factor in both genders, followed by high blood pressure. However, a higher prevalence of decreased HDL cholesterol was noted in women (28%) than in men (13.5%), whereas fasting hyperglycemia was more common among men (36.5%) than women (24%).
Table 1.
Characteristics of the subjects with and without metabolic syndrome
| |
All (n = 102) |
Men (n = 52) |
Women (n = 50) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| without MS | with MS | p value | without MS | with MS | p value | without MS | with MS | p value | |
| Total number |
71 |
31 |
|
36 (69.2%) |
16 (30.8%) |
|
35 (70.0%) |
15 (30.0%) |
|
| Age (yr) |
55.5 ± 7.8 |
56.5 ± 8.5 |
> 0.1 |
56 ± 9 |
55 ± 8 |
> 0.1 |
55 ± 6 |
58 ± 9 |
> 0.1 |
| Smoker, n (%) |
10 (14.1%) |
4 (12.9%) |
> 0.1 |
10 (27.8%) |
4 (25.0%) |
> 0.1 |
0 (0.0%) |
0 (0.0%) |
1.000 |
| Hypertension, n (%) |
14 (19.7%) |
19 (61.3%) |
< 0.0001 |
8 (22.2%) |
11 (68.8%) |
0.001 |
6 (17.1%) |
10 (53.3%) |
0.009 |
| Anti-HTN drugs, n (%) |
5 (7.0%) |
6 (19.4%) |
0.07 |
2 (5.6%) |
4 (25%) |
0.06 |
3 (8.6%) |
2 (13.3%) |
> 0.1 |
| Systolic BP (mmHg) |
114 ± 13 |
129 ± 13 |
< 0.0001 |
116 ± 12 |
128 ± 14 |
0.004 |
111 ± 13 |
131 ± 13 |
< 0.0001 |
| Diastolic BP (mmHg) |
71 ± 10 |
79 ± 9 |
0.0003 |
72 ± 10 |
79 ± 9 |
0.020 |
70 ± 10 |
79 ± 9 |
0.007 |
| Diabetes, n (%) |
2 (2.8%) |
2 (6.5%) |
> 0.1 |
1 (2.8%) |
1 (6.3%) |
> 0.1 |
1 (2.9%) |
1 (6.7%) |
> 0.1 |
| Fasting sugar (mg/dl) |
94 ± 18 |
107 ± 19 |
0.0013 |
93 ± 9 |
107 ± 15 |
0.001 |
91 ± 7 |
107 ± 23 |
0.0006 |
| Body weight (kg) |
63.0 ± 11.2 |
70.5 ± 12.6 |
0.0033 |
69.0 ± 10.7 |
77.6 ± 8.8 |
0.008 |
56.7 ± 7.8 |
63.0 ± 12.0 |
0.031 |
| Body mass index (kg/m2) |
24.1 ± 3.3 |
26.6 ± 3.6 |
0.0008 |
24.3 ± 3.4 |
26.9 ± 2.4 |
0.007 |
23.8 ± 3.2 |
26.2 ± 4.5 |
0.042 |
| Waist circumference (cm) |
82.7 ± 9.2 |
90.7 ± 7.5 |
< 0.0001 |
84.9 ± 8.6 |
92.3 ± 6.1 |
0.001 |
80.5 ± 9.5 |
89.0 ± 8.7 |
0.005 |
| Waist-hip ratio |
0.87 ± 0.07 |
0.92 ± 0.06 |
0.0019 |
0.89 ± 0.05 |
0.93 ± 0.04 |
0.006 |
0.85 ± 0.08 |
0.90 ± 0.07 |
0.046 |
| Triglyceride (mg/dl) |
95 ± 39 |
164 ± 93 |
0.0003 |
98 ± 45 |
166 ± 95 |
0.013 |
92 ± 32 |
163 ± 95 |
0.013 |
| HDL cholesterol (mg/dl) |
60 ± 14 |
50 ± 14 |
0.0008 |
55 ± 11 |
45 ± 10 |
0.003 |
66 ± 14 |
56 ± 15 |
0.022 |
| Total cholesterol (mg/dl) | 209 ± 39 | 216 ± 35 | > 0.1 | 202 ± 38 | 209 ± 37 | > 0.1 | 217 ± 38 | 224 ± 33 | > 0.1 |
The data are expressed as a number (percentage) or mean ± SD. MS, metabolic syndrome; HTN, hypertension, BP, blood pressure, HDL, high density lipoprotein.
Table 2.
Prevalence of individual metabolic syndrome component in men and women according to the number of abnormal components
| |
Men |
Women |
||||||
|---|---|---|---|---|---|---|---|---|
| |
Number of abnormal metabolic components |
Number of abnormal metabolic components |
||||||
| |
0-5 |
0-2 |
3 |
4-5 |
0-5 |
0-2 |
3 |
4-5 |
| |
(All) |
(without MS) |
(with MS) |
(with MS) |
(All) |
(without MS) |
(with MS) |
(with MS) |
| (n = 52) | (n = 36) | (n = 12) | (n = 4) | (n = 50) | (n = 35) | (n = 10) | (n = 5) | |
| Increased waist circumstance |
25 (48.1%) |
12 (33.3%) |
9 (75.0%) |
4 (100.0%) |
31 (62.0%) |
18 (51.4%) |
8 (80.0%) |
5 (100.0%) |
| Decreased HDL |
7 (13.5%) |
0 (0.0%) |
4 (33.3%) |
3 (75.0%) |
14 (28.0%) |
5 (14.3%) |
4 (40.0%) |
5 (100.0%) |
| Hypertriglycerides |
10 (19.2%) |
2 (5.6%) |
6 (50.0%) |
2 (50.0%) |
9 (18.0%) |
2 (5.7%) |
2 (20.0%) |
5 (100.0%) |
| Hyperglycemia |
19 (36.5%) |
8 (22.2%) |
7 (58.3%) |
4 (100.0%) |
12 (24.0%) |
3 (8.6%) |
6 (60.0%) |
3 (60.0%) |
| High blood pressure | 24 (46.2%) | 10 (27.8%) | 10 (83.3%) | 4 (100.0%) | 21 (42.0%) | 8 (22.9%) | 10 (100.0%) | 3 (60.0%) |
The data are expressed as a number (percentage). MS, metabolic syndrome, HDL, high density lipoprotein.
Differential expression of circulating miRNAs between MetS and non-MetS subjects
The comparisons between the MetS (n = 31) and the non-MetS subjects (n = 71) showed that the levels of both let-7 g and miR-221 were significantly elevated in the circulation of the MetS subjects (p = 0.004 for let-7 g and p = 0.01 for miR-221, Figure 1A and 1B). We further analyzed the relationship between the miRNAs levels and the number of MetS risk components. The levels of the two miRNAs were elevated with increasing numbers of MetS risk components: 0–2 components (n = 71), 3 components (n = 22), and 4–5 components (n = 9; p = 0.004 for let-7 g and p = 0.007 for miR-221, Figure 1C and 1D).
Figure 1.
Differential expression of serum miRNAs in individuals with or without MetS. (Left: A and B) Comparisons were made between subjects without MetS (n = 71) and with MetS (n = 31) through non-parametric Mann–Whitney U tests. The box plots depict the 25th-75th percentile, and the white line represents the median of each contribution. (Right: C and D) The relationships between the number of MetS risk components and the levels of miRNA was analyzed through Jonckheere-Terpstra tests. The status of MetS was converted into an ordinal variable: MetS 0–2 (n = 71), MetS 3 (n = 22), and MS 4–5 (n = 9). Differences with p < 0.05 were statistically significant.
Relationship between miRNAs and the MetS components
We further tested the relationship between each miRNA and each individual MetS component (Figure 2). Of the five components of MetS and the two obesity parameters (body mass index and waist-hip ratio), the HDL cholesterol was the only factor that exhibited a significant correlation with the level of circulating let-7 g (r = -0.212, p = 0.033 and ρ = -0.218, p = 0.028 by Pearson’s and Spearman’s correlation, respectively). The finding suggests that plasma HDL cholesterol has an inverse relationship with the level of let-7 g in the circulation. The similar result was obtained after adjusting for age and smoking status (β = -0.017, 95% confidence interval = -0.031 ~ -0.004, p = 0.014 by multiple linear regression).
Figure 2.
The associations between the individual miRNAs and the MetS risk components. Correlations between the expression level of the circulating miRNAs and the individual component of metabolic syndrome. The relationships were assessed by Pearson’s and Spearman’s correlation (r, Pearson’s correlation coefficient; ρ,Spearman’s coefficient). HDL, high-density lipoprotein cholesterol; BP, blood pressure.
Differential expression of circulating miRNAs between men and women
The sex-specific analysis showed that the miRNA expression levels were distinct between men and women (Figure 3). Among the males (n = 52), the serum miRNA levels were not significantly different between the MetS (n = 16) and the non-MetS (n = 36) individuals (p > 0.1 for both miRNAs). In contrast, the two miRNAs were significantly overexpressed in the female subjects with MetS (n = 15) compared with those without MetS (n = 35; p = 0.002 for let-7 g; p = 0.032 for miR-221). Remarkably, the increased level of either miRNAs was paralleled with an increased number of MetS risk components. However, the statistical significance was only observed in the women subjects (p = 0.002 for let-7 g; p = 0.022 for miR-221). Among the females, each MetS component was defined as high or low using the abovementioned ATPIII definition. A higher level of circulating let-7 g was significantly associated with a higher blood pressure (p = 0.023) and a lower HDL cholesterol level (p = 0.022; Figure 4). The serum miR-221 level did not exhibit any correlation with any of the MetS risk components.
Figure 3.
Differential expression of serum miRNAs in male and female subjects with and without MetS. The sample sizes of the male and female subjects were the following: MS(-) n = 36, MS(+) n = 16 in men and MS(-) n = 35, MS(+) n = 15 in women. (Left section) The comparisons between the individuals without or with MetS were conducted through non-parametric Mann–Whitney U tests. The box plots depict the 25th-75th percentile, and the white line represents the median of each contribution. (Right section) The relationships between the number of MetS risk components and the miRNA levels were analyzed by Jonckheere-Terpstra tests. The status of MetS was converted into an ordinal variable: MS score 0–2 (n = 36 in men and n = 35 in women), MS score 3 (n = 12 in men and n = 10 in women), and MS score 4–5 (n = 4 in men and n = 5 in women). Differences with p < 0.05 were statistically significant.
Figure 4.
Comparisons of the expression profiles of circulating miRNAs in women according to each abnormal components of MetS. Female subjects were separated to two groups using the criteria of individual MetS components. * Significant difference (p < 0.05) between the groups adjusted by age. All of the data were analyzed through non-parametric Mann–Whitney U tests. WC, waist circumstance; HDL, high-density lipoprotein cholesterol; TG, triglycerides; AC, fasting blood sugar; BP, blood pressure; TCHO, total cholesterol.
Discussion
The present study revealed that two miRNAs (let-7 g and miR-221) are notably overexpressed in the serum of individuals with MetS. The sex-specific analysis implied that the two miRNAs are more significantly associated with MetS in women. The level of either miRNAs increased when the number of MetS risk components increased. Furthermore, let-7 g may also affect individual MetS risk components: an increase in the let-7 g level was correlated with a high blood pressure and a low HDL cholesterol level. However, miR-221 may have a less distinguishable effect on the individual risk components. Our data suggest that circulating let-7 g and miR-221 may be associated with the development of MetS.
Intracellular miRNAs can be secreted into an extracellular environment through two distinct mechanisms: intra-vesicular transport (exosomes, microparticles, and apoptotic bodies) and extra-vesicular transport (protein and lipoprotein complexes) [11]. Secreted extracellular miRNAs serve as signaling molecules and mediate intercellular crosstalk. The present available data have been demonstrated that microvesicle-enclosed and lipoprotein-delivered miRNAs can be transferred into recipient cells and further influence cell phenotypes and functions [25,26]. However, the exact mechanism of the release for an individual miRNA from different cell types is largely unknown.
Another implication of our data is that the elevated levels of circulating let-7 g and miR-221 in the MetS subjects may affect CV complications. Vascular endothelial cells (ECs), circulating endothelial progenitor cells (EPCs), and peripheral blood components can be in direct contact, and ECs and EPCs are exposed to circulating exosomes containing miRNAs that may influence the function of these cells and eventually contribute to cardiovascular diseases. The biological functions of miRNAs in vascular walls are cell-specific. Our recent publication demonstrated that let-7 g is involved in lipid-mediated atherosclerosis by negatively regulating an oxidized low-density lipoprotein receptor, LOX-1 [27]. Transfection of let-7 g into human aortic smooth muscle cell inhibited LOX-1 and the transcriptional factor OCT-1 expression, cell proliferation and migration. In addition, we also demonstrated that let-7 g could be downregulated in the aorta of mice fed a high-fat diet and that this result was accompanied by an increase in the expression of LOX-1. The present study demonstrated that an increase in the serum let-7 g level is associated with high blood pressure and low HDL cholesterol levels in women. Both high blood pressure and low HDL-cholesterol have been described in connection with LOX-1 overexpression in atherosclerotic lesions [28,29]. It is possible that circulating let-7 g can be taken up by vascular smooth muscle cells (VSMC) to inhibit LOX-1 expression. Therefore, we hypothesize that the elevated circulating let-7 g levels in MetS subjects can be a defense mechanism through which the body fights an unfavorable lipid profile. Conversely, the elevation of the circulating miR-221 levels may aggravate the process of atherosclerosis. A previous investigation showed that the level of miR-221 in EPCs was higher in patients with coronary artery disease and the miR-221 expression inversely correlated with the number of EPCs [30]. Zhang X et al. further demonstrated that miR-221 overexpression inhibited the proliferation of endothelial progenitor cells by directly targeting PAK1 and affecting the c-Raf/MEK/ERK pathway [31]. An in vivo study in rats also indicated that the downregulation of miR-221 and miR-222 can reduce the proliferation of VSMCs and neointimal hyperplasia, both of which play important roles in arterial restenosis after intima injury [32]. It is possible that the circulating miR-221 can be taken up by these cells and that this action might interfere with cell growth. However, further studies are necessary to confirm these findings.
Recent studies suggest that the contribution of individual metabolic syndrome component to relative risks of cardiovascular diseases and heart failure differs between genders [2,3,33]. A number of mechanisms have been considered for the gender disparity in MetS-associated cardiovascular sequelae, including sex hormones, neurovascular regulation, and intrinsic myocardial geometry and function [3]. One 12-year observational study demonstrated that the association between MetS and all-cause, cardiovascular, and cardiac mortality was only seen in postmenopausal women [4]. However, the reasons for the lack of significant relationship in men and premenopausal women were unclear. The current study indicated that the elevation of the circulating let-7 g and miR-221 levels was predominant in MetS women. Of interest, 80% of the female subjects with MetS were above the median age (50 years) of natural menopause in Chinese women. Although age and cigarette smoking are leading contributors to cardiovascular risks, in our study the expression of circulating let-7 g and miR-221 were not correlated with age, and none of women had the smoking habit. Beyond their roles in glucose metabolism, let-7 g and miR-221 play a prominent role in vascular smooth muscle cells and endothelial cells [34]. Our data provide a potential clue to explore the changes of vascular pathology in individuals with MetS, especially in women. Further investigations are required to understand how let-7 g and miR-221 affect MetS-related cardiovascular complications.
It is not uncommon to find sex-specific risk factors for common diseases. Similarly, miRNA studies have also reported a sex-specific pattern. A previous investigation demonstrated that the expression of miR-30b in the brain cortex of schizophrenic patients was only reduced in female subjects [35]. The study further showed that miR-30b can be regulated by estrogen signaling in neuronal tissues. In our study, there was no difference in the expression levels of let-7 g and miR-221 between women younger (n = 11) and older (n = 39) than the age of 50 years (-9.16 vs. -9.08 for let-7 g and -9.07 vs. -9.08 for miR-221; p > 0.1 for both miRNAs). Although the absence of evidence that supports a difference in the miRNA levels between the women in these two age groups, our current data implies that the menopausal status might not be a major confounder in the relationship between the two miRNAs and MetS. In addition, we observed a similar increased pattern of circulating miRNAs in the male subjects with MetS. However, the lack of statistical significance could be due to the small sample size and the larger subsample variation in the serum miRNA levels among men without MetS. In our study, the higher prevalences of hypertension (22.2%) and smoking status (27.8%) in the non-MetS men may be a confounder to the variances.
Another important finding in this study was that the percentage of hemolyzed samples was much higher in the subjects with MetS compared with those without MetS (35.4% vs. 4.1%, p < 0.0001). Hemolysis is a major factor for the false results that are obtained in routine blood biochemistry examinations. It is also known that hemolysis will cause a release of RBC-derived miRNAs into the serum [24]. Thus, even if the degree of hemolysis is low, the interference may be substantial if there is a low abundance of miRNAs in the serum. Hemolysis can take place in vivo, in vitro, or both. In the present study, the procedures used for sample collection, handling, and centrifugation were performed under the same protocols. Of the 20 samples that were discarded due to the presence of hemolysis over the cutoff value, 17 were collected from MetS subjects. Further analysis showed that the 20 discarded samples exhibited significantly lower (p = 0.0012) HDL cholesterol (46 mg/dl) compared with the analyzed samples (57 mg/dl). Similarly, the 20 samples also had a higher level of triglycerides (264 mg/dl vs. 116 mg/dl, p < 0.0001). Therefore, the possible reasons for the disproportionate amount of hemolysis in MetS subjects include difficult vascular access due to potential atherosclerosis or changes in the RBC membrane properties [36]. The change in the circulating levels of let-7 g and miR-221 might be the net result of many microvesicles secreted from distinct tissue cells. However, let-7 g is enriched in both reticulocytes and erythrocytes, whereas miR-221 is a reticulocyte-specific miRNA [37]. If hemolysis had not been excluded, we would have overestimated the strength of the association between these two miRNAs and the occurrence of MetS.
Conclusions
Overall, we observed higher circulating levels of let-7 g and miR-221 in female subjects with MetS. However, this pattern was not detected in the male subjects. Further large-scale studies are needed to validate our findings.
Abbreviations
MetS: Metabolic syndrome; CV: Cardiovascular; miRNAs: microRNAs; HG: High glucose; HDL: High-density lipoprotein; RBC: Red blood cells; VSMC: Vascular smooth muscle cells; ECs: Endothelial cells; EPCs: Endothelial progenitor cells; LOX-1: Lectin-like oxidized low-density lipoprotein receptor-1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YTW performed experiments and PCT collected data. YTW carried out the final data analysis, created tables and figures, and wrote the manuscript. PCT and YCL contributed with valuable and critical discussion. CYH provided scientific input and participated in the preparation of the manuscript. SHHJ coordinated the study, provided content checking, and oversaw its performance. All authors read and approved the final manuscript.
Contributor Information
Yu-Ting Wang, Email: ytw530@yahoo.com.tw.
Pei-Chien Tsai, Email: pctsai1225@gmail.com.
Yi-Chu Liao, Email: yichu.liao@gmail.com.
Chung-Y Hsu, Email: hsuc@mail.cmuh.org.tw.
Suh-Hang Hank Juo, Email: hjuo@kmu.edu.tw.
Acknowledgments
This work was supported by the following grants: NHRI-Ex101-10107PI from the National Health Research Institutes of Taiwan, NSC 100-2923-B-037-001-MY3 and NSC 99-2628-B-037-037-MY3 from the National Science Council of Taiwan, and BM102021169 from Academia Sinica.
References
- Lai MM, Li CI, Kardia SL, Liu CS, Lin WY, Lee YD, Chang PC, Lin CC, Li TC. Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. BMC Public Health. 2010;10:429. doi: 10.1186/1471-2458-10-429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006;95:136–147. doi: 10.1007/s00392-006-0351-5. [DOI] [PubMed] [Google Scholar]
- Ren J, Kelley RO. Cardiac health in women with metabolic syndrome: clinical aspects and pathophysiology. Obesity (Silver Spring) 2009;17:1114–1123. doi: 10.1038/oby.2009.8. [DOI] [PubMed] [Google Scholar]
- Lin JW, Caffrey JL, Chang MH, Lin YS. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality–cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab. 2010;95:4258–4267. doi: 10.1210/jc.2010-0332. [DOI] [PubMed] [Google Scholar]
- Jakob P, Landmesser U. Role of microRNAs in stem/progenitor cells and cardiovascular repair. Cardiovasc Res. 2012;93:614–622. doi: 10.1093/cvr/cvr311. [DOI] [PubMed] [Google Scholar]
- Jamaluddin MS, Weakley SM, Zhang L, Kougias P, Lin PH, Yao Q, Chen C. miRNAs: roles and clinical applications in vascular disease. Expert Rev Mol Diagn. 2011;11:79–89. doi: 10.1586/erm.10.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91:827–887. doi: 10.1152/physrev.00006.2010. [DOI] [PubMed] [Google Scholar]
- Chen KC, Hank Juo SH. MicroRNAs in atherosclerosis. Kaohsiung J Med Sci. 2012;28:631–640. doi: 10.1016/j.kjms.2012.04.001. [DOI] [PubMed] [Google Scholar]
- Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD. et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694. doi: 10.1371/journal.pone.0003694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR) Methods. 2010;50:298–301. doi: 10.1016/j.ymeth.2010.01.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res. 2012;93:555–562. doi: 10.1093/cvr/cvr266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT, Lim SC, Sum CF, Jeyaseelan K. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab. 2012;97:E2271–2276. doi: 10.1210/jc.2012-1996. [DOI] [PubMed] [Google Scholar]
- Hulsmans M, De Keyzer D, Holvoet P. MicroRNAs regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. FASEB J. 2011;25:2515–2527. doi: 10.1096/fj.11-181149. [DOI] [PubMed] [Google Scholar]
- Heneghan HM, Miller N, McAnena OJ, O’Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011;96:E846–850. doi: 10.1210/jc.2010-2701. [DOI] [PubMed] [Google Scholar]
- Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA. 2011;108:21075–21080. doi: 10.1073/pnas.1118922109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG. et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147:81–94. doi: 10.1016/j.cell.2011.08.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li Y, Song YH, Li F, Yang T, Lu YW, Geng YJ. MicroRNA-221 regulates high glucose-induced endothelial dysfunction. Biochem Biophys Res Commun. 2009;381:81–83. doi: 10.1016/j.bbrc.2009.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE, Habeos IG. Differential Expression of MicroRNAs in Adipose Tissue after Long-Term High-Fat Diet-Induced Obesity in Mice. PLoS One. 2012;7:e34872. doi: 10.1371/journal.pone.0034872. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, Rodriguez-Hermosa JI, Ruiz B, Ricart W, Peral B, Fernandez-Real JM. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One. 2010;5:e9022. doi: 10.1371/journal.pone.0009022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes. 2009;58:1050–1057. doi: 10.2337/db08-1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li L, Wu J, Pu D, Zhao Y, Wan C, Sun L, Shen CE, Sun W, Yuan Z, Shen Q. et al. Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas. 2012;73:354–360. doi: 10.1016/j.maturitas.2012.09.008. [DOI] [PubMed] [Google Scholar]
- Chang C, Chow SN, Hu Y. Age of menopause of Chinese women in Taiwan. Suppl Int J Gynecol Obstet. 1995;49:191–192. doi: 10.1016/0020-7292(95)02354-F. [DOI] [PubMed] [Google Scholar]
- Henkelman S, Rakhorst G, Blanton J, Van Oeveren W. Standardization of incubation conditions for hemolysis testing of biomaterials. Mater Sci Eng C. 2009;29:1650–1654. doi: 10.1016/j.msec.2009.01.002. [DOI] [Google Scholar]
- Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, Van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 2011;6:e24145. doi: 10.1371/journal.pone.0024145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chen X, Liang H, Zhang J, Zen K, Zhang CY. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell. 2012;3:28–37. doi: 10.1007/s13238-012-2003-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res. 2013;100:7–18. doi: 10.1093/cvr/cvt161. [DOI] [PubMed] [Google Scholar]
- Chen KC, Hsieh IC, Hsi E, Wang YS, Dai CY, Chou WW, Juo SH. Negative feedback regulation between microRNA let-7 g and the oxLDL receptor LOX-1. J Cell Sci. 2011;124:4115–4124. doi: 10.1242/jcs.092767. [DOI] [PubMed] [Google Scholar]
- Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69:36–45. doi: 10.1016/j.cardiores.2005.09.006. [DOI] [PubMed] [Google Scholar]
- Sawamura T, Kakino A, Fujita Y. LOX-1: a multiligand receptor at the crossroads of response to danger signals. Curr Opin Lipidol. 2012;23:439–445. doi: 10.1097/MOL.0b013e32835688e4. [DOI] [PubMed] [Google Scholar]
- Minami Y, Satoh M, Maesawa C, Takahashi Y, Tabuchi T, Itoh T, Nakamura M. Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest. 2009;39:359–367. doi: 10.1111/j.1365-2362.2009.02110.x. [DOI] [PubMed] [Google Scholar]
- Zhang X, Mao H, Chen J-y, Wen S, Li D, Ye M, Lv Z. Increased expression of microRNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway. Biochem Biophys Res Commun. 2013;431:404–408. doi: 10.1016/j.bbrc.2012.12.157. [DOI] [PubMed] [Google Scholar]
- Liu X, Cheng Y, Yang J, Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012;52:245–255. doi: 10.1016/j.yjmcc.2011.11.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S. Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med. 2007;4:S162–S177. doi: 10.1016/s1550-8579(07)80056-8. [DOI] [PubMed] [Google Scholar]
- Zampetaki A, Mayr M. MicroRNAs in vascular and metabolic disease. Circ Res. 2012;110:508–522. doi: 10.1161/CIRCRESAHA.111.247445. [DOI] [PubMed] [Google Scholar]
- Mellios N, Galdzicka M, Ginns E, Baker SP, Rogaev E, Xu J, Akbarian S. Gender-Specific Reduction of Estrogen-Sensitive Small RNA, miR-30b, in Subjects With Schizophrenia. Schizophr Bull. 2012;38:433–443. doi: 10.1093/schbul/sbq091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Anichkov DA, Maksina AG, Shostak NA. Relationships between erythrocyte membrane properties and components of metabolic syndrome in women. Med Sci Monit. 2005;11:CR203–210. [PubMed] [Google Scholar]
- Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One. 2008;3:e2360. doi: 10.1371/journal.pone.0002360. [DOI] [PMC free article] [PubMed] [Google Scholar]